Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
Recent Progress
Laminin is a series of heterotrimeric proteins that contain alpha, beta and gamma subunits, assembling through a coiled domain. Laminin is the main components of basement membrane, with additional functions in tumor invasion and metastasis, along with cell migration regulation and mechanical signal transduction. In particular, The Lama3 gene codes laminin alpha3 chain which interacts with beta3 and gamma2 chains to form laminin-332, the most abundant laminin heterotrimer in the basal lamina of skin and mucosa, and is also strongly associated with cancer.
It has been indicated by genetic, clinical, and biochemical studies that to maintain the integrity of the dermal-epidermal junction, the subset of laminins that contain the chain encoded by the Lama3 gene are required. Consequently, inherited mutations or constitutive mutations in the mouse gene prevent expression of these laminins, causing junctional epidermolysis bullosa (JEB), which is a very severe and often lethal disorder characterized by detachment of the epidermis from the dermis (Fig.1). To further identify the relationship between the Lama3 gene and the disease, researchers disrupted the Lama3 gene in basal keratinocytes of adult mice, which led to the disappearance of chain-containing laminins at the dermal-epidermal junction along with formation of subepidermal blisters. The mice suffered from loss of nails, erosions on the footpads, inflammation, and development of skin fibrosis with extensive accumulation of interstitial and microfibrillar collagens. This sheds light on the possible relationship between the Lama3 gene and the disease.
Fig. 1. Junctional blisters and laminin expression in mutant skin. (C) A junctional blister present in the mutant skin that is characterized by a separation of the epidermis (e) from the dermis (d) at the BMZ. Basal cells in the lesion appear sparse and flattened (arrows). Arrows with asterisks mark cell clusters that appear undifferentiated in the superbasal cell layer. (MC Ryan et al, 2016)
While examining pedigrees of JEB patients with LAMA3 mutations, investigators observed that heterozygous carriers of functional null mutations presented subtle enamel pitting in the absence of skin fragility or other JEB symptoms. At the case report, two new LAMA3 functional null mutations were introduced: nonsense c.2377C>T p.(Arg793Ter) and splice-site c.4684+1G>A mutation which was in the heterozygous carriers exhibiting enamel pitting. It was also discovered that both parents had offspring inflicted with JEB and displayed subtle enamel pitting of secondary dentition without any sign of skin blistering. The mentioned enamel abnormality in LAMA3 mutation carriers could be attributed to a half dose effect of the laminin chain (haploinsufficiency).
Researchers also created an inducible transgenic mouse model (Lama3fl/fl/K14-Cre-ERT mouse), in which the Lama3 gene is turned off at certain time point in basal keratinocytes of the skin and mucosae. Compare to those models constantly lacking laminin-332 with early lethality, the transgenic model is viable, also allowing researchers to examine the molecular and cellular consequences caused by the loss of the laminin alpha3 chain.
Similar to the junctional epithelium, the peri-implant epithelium attaches to the surface of the implant via hemi-desmosomes (HDs) and internal basal lamina which is the extracellular matrix containing laminin332. Through layer-by-layer assembly and antibody-antigen specific binding for substrate-mediated gene transduction, researchers were able to produce a multilayer coating modified with the Lama3 on the titanium implant surface. The results in vitro indicated that the LAMA3-modified coating on the titanium surface could improve cell adhension in the early stage, and facilitate the expression of laminin α3 on both the protein and the gene levels. Also, the formation of hemidesmosomes at the interface became prominent. In vivo experiments demonstrated that the LAMA3 gene coating on the implant surface could enhance the expression of laminin α3 and improve the biological sealing between the implant and the epithelium. These findings in improving biological sealing between titanium implant and gingival epithelium offer a new approach and experimental evidence for research on the interface of the implant and soft tissues.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.